ProCE Banner Activity

CAPELLA: Wk 104 Results With Long-Acting Subcutaneous Lenacapavir in Persons Living With Multidrug-Resistant HIV

Conference Coverage
Slideset

Subcutaneous lenacapavir with optimized background regimen was associated with sustained virologic suppression and was well tolerated in heavily treatment–experienced persons living with multidrug-resistant HIV through Week 104.

Released: October 19, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare